HopeAI
HopeAI provides AI-powered solutions for clinical development, aiming to design smaller, faster, and more successful trials. Their AI Scientist team assists clinical development teams by offering data-driven insights and statistical innovations. Key products include 'PURE Evidence', which offers precise, up-to-date, reliable, and easily accessible clinical outcome data, including synthetic individual patient data. 'SynthIPD' generates synthetic individual patient data based on real clinical trial results, enabling privacy-safeguarded access to data. 'CARA Design' focuses on covariate-adjusted response adaptive randomization for precision medicine, increasing the chance of patients being randomized to superior treatments. Oncologists use their 'AI Copilot' for evidence-based medicine, gaining insights into treatment regimens and supporting clinical trials by asking questions, with the system combining AI-driven workflows and expert curation for accuracy. Collaborations with Mayo Clinic, Fred Hutch Cancer Center, and Takeda have validated associations between MRD negativity and survival endpoints in multiple myeloma.
HopeAI
HopeAI provides AI-powered solutions for clinical development, aiming to design smaller, faster, and more successful trials. Their AI Scientist team assists clinical development teams by offering data-driven insights and statistical innovations. Key products include 'PURE Evidence', which offers precise, up-to-date, reliable, and easily accessible clinical outcome data, including synthetic individual patient data. 'SynthIPD' generates synthetic individual patient data based on real clinical trial results, enabling privacy-safeguarded access to data. 'CARA Design' focuses on covariate-adjusted response adaptive randomization for precision medicine, increasing the chance of patients being randomized to superior treatments. Oncologists use their 'AI Copilot' for evidence-based medicine, gaining insights into treatment regimens and supporting clinical trials by asking questions, with the system combining AI-driven workflows and expert curation for accuracy. Collaborations with Mayo Clinic, Fred Hutch Cancer Center, and Takeda have validated associations between MRD negativity and survival endpoints in multiple myeloma.